Skip to main content
Premium Trial:

Request an Annual Quote

More Diverse Microorganism Need to Be Sequenced, Says Microbiology Report

NEW YORK, Aug 6 (GenomeWeb News) - Genomic studies, including sequencing research, should be extended to include a more diverse array of microorganisms, according to a recent report.

 

The report, released yesterday by the AmericanAcademyof Microbiology, said that this additional research may help scientists uncover a "Rosetta Stone" sequence for pathogens. This knowledge, in turn, could ultimately expedite the control and prevention of many diseases.

 

"Genomics has had a profound and lasting impact on the study of pathogens and disease, to the extent that it is difficult to imagine what the science would be like today in the absence of genomics," said Richard Roberts, the chair of a colloquium convened by the Academy in Key Largo, Fla., which was the basis of the report.

 

Sequencing the genomes of viruses and bacterial pathogens have become a first priority when investigating outbreaks and emerging infectious diseases, a report stated.

 

According to the report, more than 100 bacterial pathogens and 1,000 viruses have been sequenced since the first completed genome of a pathogenic bacterium was announced in 1995. The genomes are used globally to track and identify new diseases such as SARS, and have revolutionized the study of older diseases such as AIDS and tuberculosis.

 

Scientist recommended greatly increasing the library of genomes to include not only pathogenic microorganisms, but also sequences of their hosts, and sequences of their non-pathogenic relatives.

 

Improvements are also needed in the annotation of genomic methodologies and in sequence databases, the report said.

 

A copy of the report can be found here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more